3 Nuclear Stocks to Buy With $2,000 After One Fell 83%

NuScale’s SMR designs remain the only NRC-certified option, but revenue collapsed to $75,000 in 2Q (from $565,000 in 1Q and $8.1M in 2Q last year) as losses widened to $50.1M, leaving it dependent on future orders despite a $1.9B cash war chest. In contrast, Constellation Energy’s nuclear fleet produced 44,160 GWh in 2Q and it raised 2026 adjusted EPS guidance to $11.50–$12.50 after 34% y/y operating earnings growth to $2.55/share, while also adding long-term PPAs including a 176MW deal with Walmart. Cameco meanwhile reiterated contracted uranium deliveries averaging 28M lbs/year over the next five years, supporting a steadier cash-flow profile even as 2Q earnings fell.

Analysis

The market is still treating “nuclear” as one trade, but the cash-flow profile is three different businesses. The cleanest expression is CEG: it monetizes power demand now, and long-dated PPAs give it better visibility than the market usually pays for in a merchant-heavy utility. The risk is that the stock already discounts a lot of the AI/load-growth narrative, so any flattening in forward power prices or softer capex returns could compress the multiple even if earnings keep rising.

CCJ is the lower-beta way to own the security-of-supply theme. The contract book reduces near-term earnings volatility and makes it less dependent on the spot uranium tape, but that also means upside is more path-dependent on contract repricing than on headline reactor enthusiasm. A second-order bull case is that delayed reactor builds can still support uranium pricing if utilities keep contracting ahead of supply; the bear case is faster reactivation of supply or a pause in utility procurement.

SMR remains a venture-style financing asset, not a demand proxy. The main catalyst is not regulatory approval but conversion of approvals into financed orders; until then, dilution, extended burn, and project-timing slippage are the real equity risks. Contrarian takeaway: the market may be overpaying for the most speculative name while underappreciating that the best risk-adjusted exposure is the company already converting load growth into cash flow today.

Key Decisions for Investors

• Long CEG on any pullback over the next 1-3 months; thesis only works if 2026 guidance holds and new PPAs continue to offset merchant exposure. Falsifier: a guide cut or stalled backlog growth.
• Pair trade: long CEG / short SMR for 6-12 months. This isolates the difference between realized cash flow and future optionality. Main risk: a definitive TVA-type order plus non-dilutive financing for SMR.
• Add CCJ as a lower-volatility uranium exposure for a 6-18 month horizon. Best case is continued utility contracting and firmer long-term uranium pricing; falsifier is contracting slowdown or a sustained roll-over in long-term uranium prices.
• Avoid chasing SMR until there is a signed customer contract with financing terms. If you want convexity, use a small starter position only after order conversion, not before.